Latest news with #brainTumor
Associated Press
a day ago
- Health
- Associated Press
ZAP Surgical Announces First ZAP-X Gyroscopic Radiosurgery Patient Treatments in Latin America
SAN CARLOS, Calif.--(BUSINESS WIRE)--Jun 19, 2025-- ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced the first patient treatments using its ZAP-X® Gyroscopic Radiosurgery® platform in Latin America. Located in Neuland, Boquerón, Paraguay, Radioterapia Concordia ( ) has officially commenced clinical use, marking a major milestone in the decentralization of state-of-the-art brain tumor care across the region. This press release features multimedia. View the full release here: The ZAP-X® Gyroscopic Radiosurgery® platform at Radioterapia Concordia, Neuland, Boquerón, Paraguay In its first day of operation, four patients received next-generation stereotactic radiosurgery (SRS) with ZAP-X® for a range of intracranial conditions, including meningioma, acoustic neuroma, trigeminal neuralgia, and arteriovenous malformation (AVM). Historically, patients in the central regions of Latin America have had limited or no access to modern SRS, often requiring travel to large metropolitan hubs like Buenos Aires, São Paulo, or Santiago. Radioterapia Concordia now offers these advanced treatments locally, helping bridge a longstanding healthcare gap for rural communities. 'People in rural areas deserve to receive world-class medical care where they live, from people they understand, and at a fair price,' said Prof. Dr. Peter Douglas Klassen, Founder of Saludconcordia SA. 'With ZAP-X, we are bringing the most advanced SRS capabilities to communities that have long been underserved.' The creation of Radioterapia Concordia is further bolstered by its strategic location along the Bi-Oceanic Corridor—a transformative infrastructure project linking Brazil, Paraguay, Argentina, and Chile to improve regional access and trade. The new cancer center also benefits from its collaborative relationship with ZAP-X Zentrum Lingen in Germany, home to Europe's first ZAP-X system. 'This is more than just a technology deployment—it's a movement toward cooperative medicine,' said MBA MSc Edelgard Loewen, Case Manager at ZAP-X Zentrum Lingen. 'We're witnessing a new model emerge in Latin America—one that rises above the limitations of national and purely private healthcare systems to prioritize patients through altruistic, turnkey cancer care.' As an alternative to open brain surgery, stereotactic radiosurgery is a non-invasive, outpatient procedure used to treat many primary and metastatic brain tumors, as well as other disorders of the head and neck. Unlike traditional surgery however, SRS does not require incisions or anesthesia, and patients often return to normal activities the same day. The ZAP-X system is renowned for its unique gyroscopic design, which enables the delivery of radiosurgical beams from thousands of unique angles. This approach enhances the ability to concentrate radiation precisely on the tumor while minimizing dose to surrounding healthy brain tissue—an important factor in preserving cognitive function. ZAP-X is also the first and only vault-free SRS system, removing the need for costly shielded treatment rooms. Additionally, by utilizing a modern linear accelerator, ZAP-X eliminates the use of Cobalt-60, avoiding the exorbitant costs and regulatory burdens tied to radioactive isotopes. For more information about ZAP Surgical and the ZAP-X system, visit About ZAP Surgical Systems, Inc. ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler, Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife ® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn. View source version on CONTACT: Mark Arnold, ZAP Surgical Systems, Inc. Senior Vice President, Marketing +1 650 492 7797, ext. 101 Email:[email protected] KEYWORD: LATIN AMERICA NORTH AMERICA UNITED STATES PARAGUAY SOUTH AMERICA CALIFORNIA INDUSTRY KEYWORD: NEUROLOGY RADIOLOGY SURGERY ONCOLOGY HEALTH MEDICAL DEVICES HOSPITALS OTHER HEALTH SOURCE: ZAP Surgical Systems, Inc. Copyright Business Wire 2025. PUB: 06/19/2025 07:15 AM/DISC: 06/19/2025 07:15 AM
Daily Mail
2 days ago
- Health
- Daily Mail
Popular rock band's guitarist drops out of tour after devastating health diagnosis
Hatebreed's longtime guitarist Wayne Lozinak has withdrawn from the popular rock band's current tour after being diagnosed with a brain tumor. While on the European leg of their 'Weight of the False Self' tour, the Connecticut-based rock band's lead guitarist began experiencing mild but concerning symptoms suggestive of a possible stroke. 'On the night of June 14, while at the Download Festival, Wayne began experiencing mild symptoms that raised concerns of a possible stroke,' a social media statement from the band reads. 'Out of an abundance of caution, he sought medical attention the following day upon arriving in Lille, France.' After undergoing thorough testing, Lozinak's medical team discovered a brain tumor which required his 'immediate admission' to the medical center. 'After undergoing a CT scan at the ER, doctors discovered a brain tumor, leading to his immediate admission for further testing,' the statement continued. 'Following a 24-hour evaluation, including an MRI, it was determined that the tumor is a benign meningioma - a slow-growing mass that has likely been present for years.' The band later expressed relief for their beloved bandmate, claiming his diagnosis 'is the best possible outcome given the circumstances.' 'We are immensely relieved that Wayne's diagnosis is the best possible outcome given the circumstances,' the metalcore band wrote on Instagram. The statement adds that Lozinak will return stateside in order to prepare for and undergo surgery. The band has also confirmed that Matt Bachand of Shadows Fall will be taking over Lozniak's guitar duties for the time being. '[Lozniak's] strength and resilience remain unwavering and he is determined to return to Hatebreed as soon as he is able,' the statements adds. 'We appreciate all the love and support from fans, friends, and the music community during this time.' The metalcore group (pictured) is currently on the road in Europe playing a mix of shows with English death metal band, Carcass The group is currently on the road in Europe playing a mix of shows with English death metal band, Carcass. As part of their European tour, the 'hardcore' band will also play at various festivals. Their UK run concludes on July 6 in London, before they head back the US to kick off a North American tour leg. During their stateside leg the band will play alongside other notable rock names including Malevolence, Fugitive, Gridiron, Escuela Grind and Morbid Visionz. Incite will also play on select dates, Loudwire reported.
The Independent
2 days ago
- Health
- The Independent
‘Pioneering' technology to be used on UK brain tumour patients in world-first
A 'pioneering' new scanner developed by scientists in Scotland could significantly improve treatment for patients with glioblastoma, the most common and aggressive type of brain tumour. More than 3,000 new patients are diagnosed with glioblastoma in the UK each year, and half of all patients die within 15 months of diagnosis, even after extensive surgery, radiotherapy and chemotherapy. Scientists at the University of Aberdeen and NHS Grampian have been awarded £350,000 in funding from the Scottish Government to use field cycling imaging (FCI), a new technology derived from MRI, to track brain cancer spread by generating never-before-seen images. FCI is a new and specialist type of low-field MRI scan pioneered in Aberdeen and has already been found to be effective in detecting tumours in breast tissue and brain damage in stroke patients. It is hoped it can now be used to help brain tumour patients. MRI scanners were invented at the University of Aberdeen 50 years ago, but the new FCI scanner is the only one of its type used on patients anywhere in the world. The FCI derives from MRI but can work at low and ultra-low magnetic fields which means it is capable of seeing how organs are affected by diseases in ways that were previously not possible, and can vary the strength of the magnetic field during the patient's scan – acting like multiple scanners and extracting more information about the tissues. The new technology can detect tumours without having to inject dye into the body, which can be associated with kidney damage and allergic reactions in some patients. The team of doctors and scientists involved will scan glioblastoma patients undergoing chemotherapy after surgery and chemoradiotherapy. It is hoped the research will establish that, unlike conventional MRI scans, FCI can tell the difference between tumour growth and progression, and 'pseudo-progression' which looks like tumour but is not cancerous tissue, which could improve care and quality of life. Professor Anne Kiltie, Friends of ANCHOR chair in clinical oncology at the University of Aberdeen, who is leading the study, said: 'We already have evidence that FCI is effective in detecting tumours in breast tissue and brain damage in patients following a stroke. 'Applying this exciting new technology to glioblastoma patients could give us a much more accurate and detailed picture of what is going on in their brain. 'If we can detect true tumour progression early, we can swap the patient to a potentially more beneficial type of chemotherapy. 'Also, being able to verify that a patient has pseudo-progression will prevent effective chemotherapy being stopped too early, because it was thought that the tumour has progressed, thus worsening prognosis. 'Providing certainty will also reduce anxiety for both patients and relatives and improve the quality of life of patients. 'Importantly, having a reliable method to identify progressive disease will allow development and more precise evaluation of emerging potential treatments. This is of particular importance as patients currently have a limited choice of treatments for combating their cancer. 'Ultimately, this study and related future work will improve quality, effectiveness and healthcare cost-effectiveness in the treatment of glioblastoma patients across Scotland and beyond.' Sarah-Jane Hogg, chief executive at Friends of ANCHOR, said it was a 'really promising development and another example of the pioneering work coming out of the University of Aberdeen'. 'Professor Kiltie's role at the University is fully funded by Friends of ANCHOR through our Dream Big appeal, and our thanks go to our donors and fundraisers for the part they've played in supporting this work.' A spokesperson for The Brain Tumour Charity said: 'This pioneering technology is a promising step forward for people who have been diagnosed with the most aggressive type of brain tumour. 'It's positive news in contrast to the accounts we often hear about delays to diagnosis, limited treatment options, and the struggle to get vital innovations to the NHS front line. 'We welcome this, and The Brain Tumour Charity will continue working with clinicians and policymakers in Scotland – and the rest of the UK – to help bring advances to patients more quickly.'
Yahoo
2 days ago
- Entertainment
- Yahoo
Hatebreed Guitarist Exits Tour Following Diagnosis of Brain Tumor
Hatebreed guitarist Wayne Lozinak has announced a temporary departure from the group following the discovery of a non cancerous brain tumor. News of Lozinak's health update was shared by the band on social media on Tuesday (June 17), explaining that the guitarist had first experienced 'mild symptoms that raised concerns of a possible stroke' during their visit to England's Download Festival on Saturday (June 14). More from Billboard Young Singer Wins Over 'AGT' Judges With Ed Sheeran Cover Ozzy Osbourne's DNA Will Be Sold in Limited Edition Liquid Death Cans Kneecap Launch London Billboard Takeover Ahead of 'Witch-Hunt' Court Appearance 'Out of an abundance of caution, he sought medical attention the following day upon arriving in Lille, France,' the post explained. After undergoing a CT scan at the ER, doctors discovered a brain tumor, leading to his immediate admission for further testing. 'Following a thorough 24-hour evaluation, including an MRI, it was determined that the tumor is a benign meningioma—a slow-growing mass that has likely been present for years. We are immensely relieved that Wayne's diagnosis is the best possible outcome given the circumstances.' Currently, Lozinak is in the process of returning to the U.S. so that he can 'prepare for surgery and focus on rest and recovery.' Noting his determination to return to the band 'as soon as he is able,' the group added that in his absence, Lozinak's role will be filled by Shadows Fall's Matt Bachand. Notably, Bachand has performed in Hatebreed since November 2024, having taken over from bassist Chris Beattie following his departure from the band. In a statement shared in February, Beattie clarified that 'the decision to leave the band was not mine,' citing 'misleading and wrongful statements' as leading to his exit. Hatebreed also added that First Blood's Carl Schwartz has now taken on the role of bassist following Bachand's move to guitar. Hatebreed first formed in Bridgeport, Connecticut in 1994 and released their debut album three years later. They found widespread fame with 2002's Perseverance, which reached No. 50 on the Billboard 200, while the group later received a Grammy nomination for best metal performance in 2004. Further albums improved on their initial chart showing, with 2013's The Divinity of Purpose becoming their most commercially-successful when it peaked at No. 20 and additionally topped the Top Hard Rock Albums chart. Their most recent album, 2020's Weight of the False Self, became their first not to impact the Billboard 200 since their debut, but peaked at No. 12 on the Hard Rock Albums. Hatebreed's current Wight of the False Self Tour is making its way through Europe presently, with dates scheduled across the U.K. and North America until October. Best of Billboard Chart Rewind: In 1989, New Kids on the Block Were 'Hangin' Tough' at No. 1 Janet Jackson's Biggest Billboard Hot 100 Hits H.E.R. & Chris Brown 'Come Through' to No. 1 on Adult R&B Airplay Chart
CBS News
4 days ago
- Sport
- CBS News
North Reading baseball wins state championship after teammate finishes brain tumor treatment
We first met Brady Cullen two weeks ago when he rang the bell at Mass General, signaling the end of six-weeks of radiation to treat a brain tumor. The 16-year-old is a rising junior at North Reading High School where he served as a manager for the baseball team this season and a source of inspiration. During his 30 days of treatment, Cullen never missed school and rarely missed a game or practice. Just days after he finished treatment, he returned to his high school baseball field to throw out the first pitch at their first playoff game. Cullen would be at each playoff game to come and was with the team in Worcester over the weekend when the baseball team won their first state championship since 2012. The team beat Arlington Catholic 10-3. The North Reading High School baseball team won the state championship at Polar Park. Eric Evans "It really was a special moment that I will remember forever," said Cullen. "I looked out on the field and took it all in and said, 'you know what, we did it.' This was the most insane moment of my life. I just think someone better write a movie on it. It's a tale for all of time." Playing with a bigger purpose Eric Archambault is the head coach for the baseball team and said Cullen has been a source of inspiration for his players all season. "The kids break out of the huddle every time and it used to be 'hornets on three.' Now, it's 'Brady on three,' and having him there is such an uplifting thing," Coach Arch said. "The kids are playing with a bigger purpose and it's just awesome to see." Cullen said he is gearing up for physical therapy and hitting the gym. All in an effort to get back on the field next season. "If this [championship] isn't motivation to get back on the field, I don't know what is," Cullen said.
